Adrian P. Bracken

This study shows SS18-SSX sustains oncogenic transcription without needing SWI/SNF activity, identifies P300 as a critical co-factor, and demonstrates targeting P300 or SWI/SNF as therapeutic strategies.

This study identifies AEBP2 as a therapeutic target in EZH2-mutant lymphoma by showing its role in maintaining H3K27me2 levels through a PRC2.2 complex.

The paper identifies specific cPRC1 complexes, CBX4/PCGF4, that mediate oncogenic gene repression in DMG cells downstream of H3K27M mutation.

This study investigates EZH2 variants linked to Weaver syndrome, showing they cause dominant negative effects on H3K27 methylation, altering chromatin states and contributing to developmental disorders.